PCAS : Collaboration with Actavis for a new drug substance in late clinical phase

Longjumeau, March 25, 2014

Collaboration with Actavis for a new drug substance in late clinical phase

PCAS and Global R&D division Actavis plc have entered into a major collaboration program to develop a robust synthetic process and industrialize to tons scale a natural substance to be used in a next generation combined oral contraceptive.
The project is atypical in terms of the chemical complexity to address at commercial scale, the tight
timelines and the potential of the new drug entering phase III.
PCAS has mobilized its R&D team to meet the challenging purity and economical targets of its customer while successfully scaling-up the synthesis from an uneconomical lab process at the end of
2013 after approximately one year of intensive work. The collaboration has been successful due to a high level of professionalism and scientific knowledge on both sides supported by a very open and fluid communication between the different teams involved.
2014 will be the final year of industrialization for this active ingredient prior to the preparation of an
NDA.

About PCAS:

Founded in 1962, PCAS is an international fine and specialty chemicals group that shares an ambition for excellence with its customers, which primarily include market-leading international groups. PCAS designs and delivers the best industrial solutions for its customers' specific expectations. These various expectations all share a common demand for safety, quality, competitiveness, innovation and sustainability. PCAS also develops ranges of proprietary products based on intellectual property.

distributed by